Recent investigations have centered on the convergence of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and dopaminergic neurotransmission. While GCGR stimulators are widely employed for treating type 2 T2DM, their unexpected consequences on reward circuit